China Pharma Holdings (CPHI) EBITDA (2010 - 2026)
China Pharma Holdings (CPHI) posted EBITDA of -$1.1 million for Q1 2026, up 6.91% on a QoQ basis from -$1.2 million in Q4 2025, and down 47.28% year-over-year from -$2.1 million in Q1 2025.
China Pharma Holdings (CPHI) EBITDA (2010 - 2026) Analysis & Trends
China Pharma Holdings' EBITDA history runs 17 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- Quarterly EBITDA fell 47.28% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.6 million (up 18.81% YoY) and the FY2025 annual result came in at -$3.2 million, up 29.41% from the prior year.
- EBITDA was -$1.1 million for Q1 2026 at China Pharma Holdings, up from -$1.2 million in the prior quarter.
- Across five years, EBITDA topped out at -$397479.0 in Q1 2023 and bottomed at -$1.4 million in Q2 2024.
- A 5-year average of -$896823.8 and a median of -$911718.0 in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA soared 56.4% — and 2024, when it tumbled 204.95%.
- China Pharma Holdings' EBITDA stood at -$1.2 million in 2022, then fell by 1.32% to -$1.2 million in 2023, then dropped by 0.97% to -$1.2 million in 2024, then decreased by 0.35% to -$1.2 million in 2025, then grew by 6.91% to -$1.1 million in 2026.
- Business Quant data shows CPHI's EBITDA at -$1.1 million in Q1 2026, -$1.2 million in Q4 2025, and -$628145.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.12 Mn |
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | -628,145.00 |
| Jun 30, 2025 | -652,120.00 |
| Mar 31, 2025 | -758,618.00 |
| Dec 31, 2024 | -1.20 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -1.39 Mn |
| Mar 31, 2024 | -916,052.00 |
| Dec 31, 2023 | -1.18 Mn |
| Sep 30, 2023 | -713,542.00 |
| Jun 30, 2023 | -456,308.00 |
| Mar 31, 2023 | -397,479.00 |
| Dec 31, 2022 | -1.17 Mn |
| Sep 30, 2022 | -688,654.00 |
| Jun 30, 2022 | -779,593.00 |
| Mar 31, 2022 | -911,718.00 |
| Dec 31, 2021 | -648,690.00 |
| Sep 30, 2021 | -762,404.00 |
| Jun 30, 2021 | -752,948.00 |